Skip to content

Pomalidomide

Pomalyst, Imnovid, Pomalidomide Celgene (pomalidomide) is a small molecule pharmaceutical. Pomalidomide was first approved as Pomalyst on 2013-02-08. It is used to treat kaposi sarcoma and multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon. Pomalyst's patents are valid until 2031-06-21 (FDA).
Trade Name Imnovid, Pomalidomide Celgene
Common Name Pomalidomide
Indication kaposi sarcoma, multiple myeloma
Drug Class Thalidomide derivatives
Pomalidomide
Get full access now